Revolade approved for treatment of aplastic anaemia

Revolade (eltrombopag) is the first drug to be licensed in the UK for use in patients with acquired severe aplastic anaemia (SAA) who are either refractory to prior immunosuppressive therapy or heavily pretreated and unsuitable for haematopoietic stem cell transplantation (HSCT).

Further information
View Revolade drug record
Summary of Product Characteristics
Manufacturer: Novartis

The current standard of care for SAA includes immunosuppressive therapy or HSCT. Approximately 40% of patients unresponsive to initial immunosuppressive therapy die from infection or bleeding within five years of their diagnosis. 

Revolade is also indicated in chronic immune thrombocytopenic purpura and in thrombocytopenia in patients with hepatitis C.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

New tablet treatment for eczema

New tablet treatment for eczema

Prescribers have a new oral treatment option for patients...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...